Company’s 36-month beta value is 0.41.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy”, 2 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for RNAC is 8.31M, and currently, short sellers hold a 31.62% ratio of that floaft. The average trading volume of RNAC on July 04, 2025 was 89.08K shares.
RNAC stock’s latest price update
Cartesian Therapeutics Inc (NASDAQ: RNAC) has experienced a decline in its stock price by -1.41% compared to its previous closing price of $11.37. However, the company has seen a fall of -2.18% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
RNAC’s Market Performance
RNAC’s stock has fallen by -2.18% in the past week, with a monthly rise of 13.23% and a quarterly drop of -13.44%. The volatility ratio for the week is 8.70% while the volatility levels for the last 30 days are 7.94% for Cartesian Therapeutics Inc The simple moving average for the last 20 days is 6.82% for RNAC’s stock, with a simple moving average of -30.81% for the last 200 days.
Analysts’ Opinion of RNAC
Many brokerage firms have already submitted their reports for RNAC stocks, with BTIG Research repeating the rating for RNAC by listing it as a “Buy”. The predicted price for RNAC in the upcoming period, according to BTIG Research is $42 based on the research report published on December 19, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to RNAC, setting the target price at $50 in the report published on June 04th of the previous year.
RNAC Trading at 6.50% from the 50-Day Moving Average
After a stumble in the market that brought RNAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.70% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 8.70%, as shares surge +17.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.44% lower at present.
During the last 5 trading sessions, RNAC fell by -2.18%, which changed the moving average for the period of 200-days by -33.07% in comparison to the 20-day moving average, which settled at $10.49. In addition, Cartesian Therapeutics Inc saw -53.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAC starting from SPRINGER TIMOTHY A, who purchase 48,595 shares at the price of $10.47 back on Apr 10 ’25. After this action, SPRINGER TIMOTHY A now owns 620,175 shares of Cartesian Therapeutics Inc, valued at $508,751 using the latest closing price.
SPRINGER TIMOTHY A, the Director of Cartesian Therapeutics Inc, purchase 41,782 shares at $9.43 during a trade that took place back on Apr 09 ’25, which means that SPRINGER TIMOTHY A is holding 571,580 shares at $393,947 based on the most recent closing price.
Stock Fundamentals for RNAC
Current profitability levels for the company are sitting at:
- -1.53% for the present operating margin
- 0.99% for the gross margin
The net margin for Cartesian Therapeutics Inc stands at -1.12%. The total capital return value is set at -0.13%. Equity return is now at value -938.38%, with -102.11% for asset returns.
Based on Cartesian Therapeutics Inc (RNAC), the company’s capital structure generated -1.82 points at debt to capital in total, while cash flow to debt ratio is standing at -2.19.
Currently, EBITDA for the company is -77.14 million with net debt to EBITDA at 4.15. When we switch over and look at the enterprise to sales, we see a ratio of 3.65. The receivables turnover for the company is 19.36for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.34.
Conclusion
In a nutshell, Cartesian Therapeutics Inc (RNAC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
